Soligenix publishes Phase 2a study results for SGX945 in Behçet's Disease treatment.

Soligenix has published the results of a Phase 2a study evaluating SGX945 (dusquetide) in the treatment of Behçet's Disease. The study showed beneficial effects for 7 of 8 patients and a potentially enduring effect through 4 weeks of follow-up. SGX945 is a peptide inhibitor of IL-1α and IL-1β that has shown promise in treating this difficult-to-treat orphan disease.